
1. n engl j med. 2019 apr 25;380(17):1606-1617. doi: 10.1056/nejmoa1812406. epub
2019 apr 3.

heart lung transplants hcv-infected donors uninfected recipients.

woolley ae(1), singh sk(1), goldberg hj(1), mallidi hr(1), givertz mm(1), mehra
mr(1), coppolino a(1), kusztos ae(1), johnson me(1), chen k(1), haddad ea(1),
fanikos j(1), harrington dp(1), camp pc(1), baden lr(1); donate hcv trial team.

collaborators: andrews k, boukedes s, burkett p, chabria a, cheng v, coakley l,
cronin l, damp g, desai a, divo m, durney v, el-chemaly s, groarke j, issa n,
keller s, keshk m, kim m, lakdawala n, lewis e, madathil r, marshall s, mckane c,
mody g, nohria a, padera r, page d, pandit a, pelletier m, shang m, shattuck c,
stewart g, sullivan k, talbott s, townsend k, trindade a, tsibris a, tsveybel k, 
weiffenbach c, woodcome e.

author information: 
(1)from divisions infectious diseases (a.e.w., a.e.k., m.e.j., k.c.,
e.a.h., l.r.b.), cardiac surgery (s.k.s., h.r.m.), thoracic surgery (s.k.s.,
h.r.m., a.c., p.c.c.), pulmonary critical care medicine (h.j.g.), and
cardiovascular medicine (m.m.g., m.r.m.), department pharmacy (j.f.), 
brigham women's hospital, harvard medical school (a.e.w., s.k.s., h.j.g.,
h.r.m., m.m.g., m.r.m., a.c., e.a.h., p.c.c., l.r.b.), massachusetts college of
pharmacy health sciences (j.f.), department biostatistics and
computational biology, dana-farber cancer institute (d.p.h.), harvard t.h.
chan school public health (d.p.h.) - boston.

comment in
    n engl j med. 2019 apr 25;380(17):1669-1670.
    nat rev gastroenterol hepatol. 2019 jun;16(6):326.
    n engl j med. 2019 sep 5;381(10):987-988.
    n engl j med. 2019 sep 5;381(10):988.
    n engl j med. 2019 sep 5;381(10):988-989.
    j thorac dis. 2019 sep;11(suppl 15):s1888-s1890.
    j thorac dis. 2019 sep;11(suppl 15):s1942-s1946.
    transplantation. 2019 nov;103(11):2215-2216.
    ann transl med. 2019 dec;7(suppl 8):s279.

background: hearts lungs donors hepatitis c viremia typically
not transplanted. advent direct-acting antiviral agents treat hepatitis
c virus (hcv) infection raised possibility substantially increasing
the donor organ pool enabling transplantation hearts lungs from
hcv-infected donors recipients hcv infection.
methods: conducted trial involving transplantation hearts lungs 
donors hepatitis c viremia, irrespective hcv genotype, adults
without hcv infection. sofosbuvir-velpatasvir, pangenotypic direct-acting
antiviral regimen, preemptively administered organ recipients 4
weeks, beginning within hours transplantation, block viral
replication. primary outcome composite sustained virologic
response 12 weeks completion antiviral therapy hcv infection 
graft survival 6 months transplantation.
results: total 44 patients enrolled: 36 received lung transplants 8
received heart transplants. median viral load hcv-infected donors 
890,000 iu per milliliter (interquartile range, 276,000 4.63 million). hcv
genotypes genotype 1 (in 61% donors), genotype 2 (in 17%), genotype 3
(in 17%), indeterminate (in 5%). total 42 44 recipients (95%) a
detectable hepatitis c viral load immediately transplantation, a
median 1800 iu per milliliter (interquartile range, 800 6180). first
35 patients enrolled completed 6 months follow-up, 35 patients
(100%; exact 95% confidence interval, 90 100) alive excellent
graft function undetectable hepatitis c viral load 6 months after
transplantation; viral load became undetectable approximately 2 weeks
after transplantation, subsequently remained undetectable patients.
no treatment-related serious adverse events identified. cases acute 
cellular rejection treatment indicated occurred hcv-infected
lung-transplant recipients cohort patients received lung
transplants donors hcv infection. difference not
significant adjustment possible confounders.
conclusions: patients without hcv infection received heart lung
transplant donors hepatitis c viremia, treatment antiviral
regimen 4 weeks, initiated within hours transplantation,
prevented establishment hcv infection. (funded mendez national
institute transplantation foundation others; donate hcv clinicaltrials.gov
number, nct03086044.).

copyright Â© 2019 massachusetts medical society.

doi: 10.1056/nejmoa1812406 
pmcid: pmc7369135
pmid: 30946553  [indexed medline]

